Halo Pharmaceutical Inc. has applied to import Schedule I psilocybin for formulation development and clinical trials, with public comments due by 18 November 2026.

Halo Pharmaceutical Inc., based in Whippany, New Jersey, applied to register as an importer of psilocybin, drug code 7437. Any authorisation would be limited to the specified basic class and would not cover FDA-approved or non-approved finished dosage forms for commercial sale. Comments and hearing requests are due through Regulations.gov by 18 November 2026 under Docket No. DEA-1779.